Platform Specialty Products Corporation Announces Receipt of Final Regulatory Approvals for the Sale of Arysta LifeScience an...

Preliminary Estimated Unaudited Full Year 2018 Results Conference Call on January 28, 2019

Platform Specialty Products Corporation (NYSE:PAH) ("Platform"), a global specialty chemicals company, announced today that all regulatory approvals necessary to complete the previously-announced sale of Platform’s Agricultural Solutions business, which consists of Arysta LifeScience Inc. and its subsidiaries (collectively “Arysta”), to UPL Corporation Ltd have been obtained. The Arysta sale is expected to close on January 31, 2019.

Platform also announced today that it will host a conference call for investors on Monday, January 28, 2019 at 8:30 a.m. (Eastern Time) to provide preliminary estimated unaudited fourth quarter and full year 2018 financial results.  Platform will also discuss its 2019 fiscal year outlook and longer-term vision for the company following completion of the Arysta transaction.

To listen to the call by telephone, please dial 877-876-9173 (domestic) or 785-424-1667 (international) and provide the Conference ID: PAHQ418. The call will be simultaneously webcast at www.platformspecialtyproducts.com. A replay of the call will be available for three weeks shortly after completion of the live call at www.platformspecialtyproducts.com.

About Platform

Platform is a leading specialty chemicals company which formulates a broad range of solutions that enhance the performance of products people use every day.  Developed in multi-step technological processes, the Company's innovative solutions enable its customers' manufacturing processes in several key industries, including consumer electronic, communication infrastructure, automotive, industrial surface finishing, consumer packaging and offshore oil production and drilling.

More information on Platform is available at www.platformspecialtyproducts.com.

Forward-looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the timing of the completion of the sale of Arysta LifeScience and the ability of the parties to close this transaction, including meeting other closing conditions. Actual results could differ from those projected due to numerous factors, including, without limitation, the parties’ ability to successfully satisfy the closing conditions and complete the proposed separation; the timing for completion; unanticipated delays; and legal, tax and regulatory requirements. Additional information concerning these and other factors that could cause actual results to vary is, or will be, included in Platform's periodic and other reports filed with the Securities and Exchange Commission, including Platform's annual report on Form 10-K for the year ended December 31, 2017.  These forward-looking statements are made as of the date of this press release and are based on management's estimates, assumptions and expectations with respect to future events and financial performance. Platform undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Investor Relations Contact:

   Carey Dorman   Corporate Treasurer and VP, Investor Relations   Platform Specialty Products Corporation   1-561-406-8465

Media Contact:

   Liz Cohen   Managing Director   Kekst & Co.   1-212-521-4845